Research programme: Natural Killer receptor inhibitor - BioLineRx

Drug Profile

Research programme: Natural Killer receptor inhibitor - BioLineRx

Alternative Names: BL-9020; EDP 10; Natural cytotoxicity triggering receptor inhibitor - BioLineRx - BioLineRx; NKp46 inhibitor - BioLineRx

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ben Gurion University; Hebrew University of Jerusalem
  • Developer Ben Gurion University; BioLineRx; Hebrew University of Jerusalem
  • Class Monoclonal antibodies
  • Mechanism of Action Natural cytotoxicity triggering receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in Israel
  • 11 Mar 2015 Pharmacodynamics data from preclinical studies released by BioLineRx
  • 08 Jan 2014 BL 9020 licensed to JHL Biotech in China and South-East Asia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top